Robeco Institutional Asset Management B.V. Has $108.14 Million Position in Quest Diagnostics Inc (DGX)

Robeco Institutional Asset Management B.V. raised its stake in shares of Quest Diagnostics Inc (NYSE:DGX) by 0.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,002,073 shares of the medical research company’s stock after purchasing an additional 2,385 shares during the period. Robeco Institutional Asset Management B.V. owned 0.74% of Quest Diagnostics worth $108,139,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in DGX. Migdal Insurance & Financial Holdings Ltd. raised its position in Quest Diagnostics by 8,866.7% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,076 shares of the medical research company’s stock worth $118,000 after purchasing an additional 1,064 shares during the last quarter. Fort L.P. bought a new position in shares of Quest Diagnostics in the 2nd quarter worth about $121,000. Capital Advisors Ltd. LLC bought a new position in shares of Quest Diagnostics in the 3rd quarter worth about $123,000. Flagship Harbor Advisors LLC bought a new position in shares of Quest Diagnostics in the 2nd quarter worth about $126,000. Finally, Dupont Capital Management Corp raised its position in shares of Quest Diagnostics by 64.4% in the 2nd quarter. Dupont Capital Management Corp now owns 1,202 shares of the medical research company’s stock worth $132,000 after acquiring an additional 471 shares in the last quarter. 86.55% of the stock is owned by institutional investors and hedge funds.

Shares of DGX opened at $97.33 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.15 and a quick ratio of 1.09. The stock has a market capitalization of $13.27 billion, a PE ratio of 18.02, a PEG ratio of 1.76 and a beta of 0.90. Quest Diagnostics Inc has a one year low of $90.31 and a one year high of $116.49.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Tuesday, October 23rd. The medical research company reported $1.68 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.68. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.95 billion. Quest Diagnostics had a return on equity of 15.71% and a net margin of 11.30%. The firm’s revenue for the quarter was up 1.8% compared to the same quarter last year. During the same period last year, the business posted $1.38 EPS. On average, sell-side analysts forecast that Quest Diagnostics Inc will post 6.56 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, October 22nd. Stockholders of record on Friday, October 5th were paid a $0.50 dividend. The ex-dividend date of this dividend was Thursday, October 4th. This represents a $2.00 annualized dividend and a dividend yield of 2.05%. Quest Diagnostics’s dividend payout ratio is presently 37.04%.

Several research firms have recently weighed in on DGX. JPMorgan Chase & Co. lowered their price objective on Quest Diagnostics from $114.00 to $107.00 and set a “neutral” rating for the company in a research report on Wednesday, October 24th. Argus set a $120.00 price objective on Quest Diagnostics and gave the stock a “buy” rating in a research report on Friday, September 14th. William Blair reissued an “outperform” rating on shares of Quest Diagnostics in a research report on Tuesday, October 23rd. Credit Suisse Group lifted their price objective on Quest Diagnostics from $121.00 to $128.00 and gave the stock an “outperform” rating in a research report on Monday, September 24th. Finally, Canaccord Genuity lowered their price objective on Quest Diagnostics from $118.00 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, October 24th. Eight investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Quest Diagnostics has a consensus rating of “Buy” and an average price target of $111.13.

TRADEMARK VIOLATION WARNING: “Robeco Institutional Asset Management B.V. Has $108.14 Million Position in Quest Diagnostics Inc (DGX)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/11/10/robeco-institutional-asset-management-b-v-has-108-14-million-position-in-quest-diagnostics-inc-dgx.html.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Featured Article: How are the companies in the S&P 500 selected?

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply